Figure 1: Pipeline for developing circulating and urine miRNAs as biomarkers of disease, with important considerations shown. Study design is critical and will influence all aspects of the methodology. Clinical evaluation and translation, including clinical trials, commercialisation, and approval, have been discussed elsewhere (e.g., see [13]) and are not included in this paper.